Panacea Biotec Limited is an Indian pharmaceutical company that is engaged in research, development, and manufacturing of pharmaceuticals, vaccines, and natural products.
Categories
Pharmaceutical
Can Jubilant Pharmova leverage their position?
“In FY24, Company’s profitability is expected to improve, driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in
Glenmark Pharmaceuticals: An Uphill Battle
“Strategic priority is to enhance our free cash generation and further debt reduction and we continue discussion with potential partners for out-licensing
Sun Pharma Advanced Research Q3FY23 Earnings
(SPARC) Sun Pharma Advanced Research Company Limited conducts pharmaceutical product research and development (R&D). Financial Results: After nine consecutive quarters of losses,
Shilpa Medicare Limited Q3FY23 Earnings
With cutting-edge technology, Shilpa Medicare is in the business of manufacturing high-quality Active Pharmaceutical Ingredients, Intermediates, Formulations, Novel Drug delivery system, Peptides,
Sanofi India Limited Q3FY23 Earnings Story
Sanofi India primarily deals with the Manufacture and sale of pharmaceutical products. Financial Results: The company reported a decline of 2.32% YoY
Procter & Gamble Health Q2FY23 Earnings Story
Procter & Gamble Health Ltd. primarily deals with both manufacturing and marketing various chemicals and pharmaceuticals. Financial Results: Procter & Gamble Health
NATCO Pharma Limited Q3FY23 Earnings
A pharmaceutical firm with a strong focus on research and development, NATCO Pharma Ltd creates, produces, and markets sophisticated pharmaceuticals for specialised
Pfizer Limited Q3FY23 Earnings Story
Pfizer Ltd is primarily involved in marketing, exporting, manufacturing, and trading of pharmaceutical products. It produces goods through its in-house facility and
Panacea Biotec Q3FY23; 26% Fall in Revenue
Panacea Biotec Limited’s revenue in Q3FY23 fell 26% to ₹ 11,520 lakhs. Consolidated Profit After Tax came at ₹ 1,937 lakhs in
Lupin Ltd (LUPIN) Q3 FY23 Earnings Concall Transcript
Lupin Ltd (NSE:LUPIN) Q3 FY23 Earnings Concall dated Feb. 10, 2023. Corporate Participants: Vinita Gupta -- Chief Executive Officer Ramesh Swaminathan -- Executive Director, Global Chief
Lupin Limited Q3FY23; 47% Growth in Profits
Lupin Limited’s revenue in Q3FY23 rose 13% to ₹ 1,97,66,301 lakhs. Consolidated Profit After Tax came at ₹ 8,34,871 lakhs in Q3FY23
Sun Pharmaceutical Q3FY23; 3% Growth in Profits
Sun Pharmaceutical Industries Limited’s revenue in Q3FY23 rose 14% to ₹ 112,410 millions. Consolidated Profit After Tax came at ₹ 21,808 millions
Aurobindo Pharma Q2FY23; 41% Fall in Profits
Aurobindo Pharma Ltd.‘s revenue in Q2FY23 fell 3% to ₹ 5,739 crores. Consolidated Profit came at ₹ 409 crores showcasing a 41%
Divi’s Laboratories Q2FY23; 19% Fall in Profits
Divi's Laboratories Ltd.'s revenues in Q2FY23 fell 7% to ₹ 1,855 crores. Consolidated Profit came at ₹ 494 crores showcasing a 19%
Torrent Pharmaceuticals Limited Q2FY23; Profits down by 1%
Torrent Pharmaceuticals Ltd.‘s Revenues for Q2 FY23 has increased by 7% YoY to ₹ 2,291 crores. Net Profit fell by 1% YoY
Apollo Hospitals Enterprise Limited Q1FY23; 35% fall in Profits
Revenue for Q1 FY23 has increased by 1% YoY to ₹ 37,956 millions. Profits have fallen by 35% YoY to ₹ 31,711
Aurobindo Pharma Limited Q1FY23; 32% fall in Profits
Revenue for Q1 FY23 has increased by 9% YoY to ₹ 6,235.9 crores. Profits have fallen by 32% YoY to ₹ 520.5
Zydus Lifesciences Ltd Q1FY23; Profit suffer with rise in expenses
Revenue for Q1 FY23 has increased by 1.8% YoY to ₹40,727 millions. Profits decreased by 12% YoY to ₹5,183 millions because Total
Piramal Enterprises Limited Q1FY23; 8% fall in Profits
Revenue for Q1 FY23 has increased by 22% YoY to ₹ 3,548 crores. Profits have fallen by 8% YoY to ₹ 496.09
Dr Reddy’s Laboratories Ltd. Q1FY23; 6% growth in Revenue
Revenue for Q1 FY23 has increased by 6% YoY to ₹ 52,154 millions. Profits have grown by 108% YoY to ₹ 11,876